Motesanib Diphosphate (AMG-706) is an investigational drug primarily studied for its potential in cancer treatment, particularly in targeting tumors driven by abnormal angiogenesis, such as iodine-refractory thyroid cancer. It works by inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and stem cell factor receptors (KIT), which are crucial for the growth and survival of cancer cells. This makes it a candidate for treating various cancers, including thyroid, lung, breast, and colorectal cancers. Clinical trials have explored its efficacy in reducing tumor size and slowing disease progression, especially in cases where standard therapies have failed. Additionally, its role in combination therapies is being studied to enhance the overall effectiveness of cancer treatment regimens. Use must be under close medical supervision due to potential severe side effects.